Learning Center
Plans & pricing Sign in
Sign Out

malignancy peritoneal mesothelioma


									A systematic review on the efficacy of cytoreductive surgery combined with
perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal

Background: within the past, diffuse malignant peritoneal mesothelioma (DMPM) was
considered a preterminal condition. The length of survival was dependent upon the
aggressive versus indolent biologic behavior of the neoplasm. the general median survival
was ∼1 year when systemic chemotherapy. Cytoreductive surgery (CRS) combined with
perioperative intraperitoneal chemotherapy (PIC) has been used as a treatment different,
however the efficacy of this combined treatment remains to be established.

Patients and methods: Searches for relevant studies printed in peer-reviewed medical journals
on CRS and PIC for DMPM before might 2006 were dole out on six databases. The reference
lists of all retrieved articles were reviewed for additional identification of doubtless relevant
studies. skilled educational surgeons in Washington, DC, USA were asked whether or not
they knew regarding any vital unpublished information. 2 investigators independently
evaluated every study in step with predefined criteria. the standard of every study was
assessed. Clinical effectiveness was synthesized through a narrative review with full
tabulation of results of all included studies.

Results: Seven prospective observational studies from six tertiary establishments were
accessible, permitting 240 DMPM patients for assessment. The median survival ranged from
34–92 months. The 1-, 3- and 5-year survival varied from hour to half of one mile, forty third
to sixty fifth and twenty ninth to fifty nine, respectively. The perioperative morbidity varied
from twenty fifth to four-hundredth and mortality ranged from third to eight.

Conclusions: This systematic review evaluated this proof for CRS and PIC for DMPM. Seven
observational studies were accessible for assessment, that demonstrated an improved overall
survival, as compared to historical controls, using systemic chemotherapy and palliative

To top